Title Page

- **Construction and Validation of a Nomogram**
- **Based on the Log Odds of Positive Lymph**
- 4 Nodes to Predict the Prognosis of Lung
- 5 Neuroendocrine Tumors
- 7 **Running title**: LODDS in lung neuroendocrine tumors
- 9 Suyu Wang^{1†}, Juan Wei^{2†}, Yibin Guo^{3†}, Qiumeng Xu^{4†}, Xin Lv², Yue Yu^{1*},
- 10 Meiyun Liu^{2*}

1

6

8

- ¹Department of Cardiothoracic Surgery, Changzheng Hospital, Naval Medical
- 12 University, Shanghai, People's Republic of China.
- ²Department of Anesthesiology, Shanghai Pulmonary Hospital, Tongji University
- 14 School of Medicine, Shanghai, People's Republic of China.
- ³Department of Health Statistics, Naval Medical University, Shanghai, People's
- 16 Republic of China.
- ⁴Department of Orthopaedics, Changzheng Hospital, Naval Medical University,
- 18 Shanghai, People's Republic of China.
- 20 *Correspondence to:

19

- 21 Meiyun Liu, MD. Department of Anesthesiology, Shanghai Pulmonary Hospital,
- 22 Tongji University School of Medicine, Shanghai, People's Republic of China.
- 23 Address: No.507 Zhengmin Road, Yangpu District, Shanghai, 200433, People's
- 24 Republic of China. Tel: (86) 18916380529, Email: liumeiyun0@126.com.
- 25 Yue Yu, MD. Department of Cardiothoracic Surgery, Changzheng Hospital, Naval
- 26 Medical University, Shanghai, People's Republic of China. Address: No.415
- Fengyang Road, Huangpu District, Shanghai, 200003, People's Republic of China.
- Tel: (86) 13601989808, Fax: 021-81885901, Email: 15021567170@153.com.
- These authors have contributed equally to this work and share first authorship.

Abstract

29

31

32

- 33 *Objectives:* This study aimed to investigate the prognostic value of Log odds of
- 34 positive lymph nodes (LODDS) for predicting the long-term prognosis of patients
- with node-positive lung neuroendocrine tumors (LNETs).
- 36 *Materials and Methods:* We collected 506 eligible patients with resected N1/N2
- 37 classification LNETs from the Surveillance, Epidemiology, and End Results (SEER)
- database between 2004 and 2015. First, we applied the Cox proportional-hazards
- 39 regression model to evaluate the relationship between LODDS and study endpoints
- 40 (cancer-specific survival [CSS] and overall survival [OS]) based on the entire cohort.
- 41 Second, the study cohort was divided into derivation cohort (n=300) and external
- 42 validation cohort (n=206) based on different geographic regions. Nomograms were

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

constructed and validated based on these two cohorts to predict the 1-, 3- and 5-year survival of patients with LNETs. The accuracy and clinical practicability of nomograms were tested and compared by Harrell's concordance index (C-index), integrated discrimination improvement (IDI), net reclassification improvement (NRI), calibration plots, and decision curve analyses. Results: The Cox proportional-hazards model showed the high LODDS group (-0.33≤ LODDS≤1.14) had significantly higher mortality compared to those in the low LODDS group (-1.44≤LODDS<-0.33) for both CSS and OS. In addition, besides LODDS, age at diagnosis, histotype, type of surgery, radiotherapy, and chemotherapy were shown as independent predictors in Cox regression analyses and included in the nomograms. The values of c-index, NRI, and IDI indicated that the established nomogram performed significantly better than the conventional eighth edition of the TNM staging system alone. The calibration plots for predictions of the 1-, 3-, and 5-year OS were in excellent agreement. Decision curve analyses showed that the nomogram had value in terms of clinical application. Conclusions: We created visualized nomograms for CSS and OS of LNET patients, facilitating clinicians to provide highly individualized risk assessment and therapy. **Keywords:** lung neuroendocrine tumors, log odds of positive lymph nodes, predictor, survival, nomogram. **Abbreviations:**

64 LNET: lung neuroendocrine tumor; TC: typical carcinoid; AC: atypical carcinoid;

LCNEC: large cell neuroendocrine carcinoma; SCLC: small cell lung carcinoma; NSCLC: non-small cell lung cancer; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control; TNM: tumor-node-metastasis; LN: lymph node; NPLN: number of positive lymph node; LODDS: log odds of positive lymph nodes; SEER: Surveillance, Epidemiology, and End Results; NDLN: number of dissected lymph node; CSS: lung cancer-specific survival; OS: overall survival; SD: standard deviation; IQR: interquartile range; HR: hazard ratio; CI: confidence interval; PRCDA: purchased/referred care delivery area; c-index: concordance index; IDI: integrated discrimination improvement; NRI: net reclassification improvement; DCA: decision curve analysis; LNR: lymph node ratio; IASLC: International Association for the Study of Lung Cancer.

Main Text

1. Introduction

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

Lung neuroendocrine tumors (LNETs) originate from pulmonary neuroendocrine cells, accounting for approximately 25% of primary lung neoplasms [1]. Owing to the increased lung cancer screening, the annual incidence of LNET has substantially increased, rising from 0.0003% in 1973 to 0.0014% in 2004 in the United States [2-4]. Currently, the 2015 World Health Organization classification has grouped LNETs into four histologic variants based on their histopathologic features: typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC), and small cell lung carcinoma (SCLC) [5]. Due to the rarity and morphological heterogeneity of these tumors, there have been limited clinical data available regarding LNETs, thus making their diagnosis, staging, risk assessment, and treatment challenging [1]. Although specific to non-small cell lung cancer (NSCLC), the international American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) tumor-node-metastasis (TNM) staging system has been applied to LNETs [6, 7]. However, several studies have shown an overlapping survival of patients with LNETs, particularly in stages II and III [6-10]. Therefore, further investigation is warranted to optimize the staging system for LNETs. Lymph node (LN) involvement is a significant prognostic factor for staging and risk stratification. A combination of the number of positive lymph nodes (NPLN), the number of negative lymph nodes, and the anatomic location of LN metastasis have been applied in the staging of many malignancies [11-15]. However, the latest version

of AJCC/UICC TNM classification of lung cancer did not take account of any number- or ratio-based LN staging system, which could affect the precision of prognosis evaluation [16, 17]. Log odds of positive lymph nodes (LODDS), defined as the logarithm of the ratio between NPLN and NNLN, is currently being used as a novel prognostic indicator with a strong ability to identify patients with a homogeneous prognosis in many malignant tumors, including NSCLC [18-21]. However, no specific study has focused on its prognostic significance in LNETs till now.

The present study aimed to determine whether LODDS could be utilized to predict the long-term prognosis of patients with node-positive (N1/N2 classification) LNET using the Surveillance, Epidemiology, and End Results (SEER) database. To facilitate clinical use, we also constructed a visualized and online nomogram incorporating LODDS for LNETs.

2. Materials and methods

2.1 Study design, data source, and ethical statement

We conducted a multi-center retrospective cohort study according to the parts of the methods described in our previous studies [20-22]. We use the Transparent Reporting of a multivariate prediction model for Individual Prediction or Diagnosis (TRIPOD) for reporting [23]. The data of this study were extracted from the SEER 18 registries research database, covering approximately 28% of the population of the United States [24]. Data were extracted using the SEER*Stat version 8.3.5 software. The

requirement for informed consent was waived because the study utilized the anonymous data available in the database. In summary, this study complied with the Declaration of Helsinki [25].

2.2 Population selection

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

Data on the patients with lung cancer were obtained from the SEER database. Inclusion criteria were as followed: (1) diagnosed from 2004 to 2015; (2) site recode "ICD-O-3/WHO 2008" restricted to "Lung and Bronchus"; and (3) pathologically confirmed as TC (ICD-O-3 code: 8240/3), AC (ICD-O-3 code: 8249/3) or LCNEC (ICD-O-3 code: 8013/3). The study period was set from 2004 to 2015, as the TMN classification and Collaborative Stage information was available in the database since 2004. Besides, we reclassified the TNM stage according to the eighth edition of AJCC/UICC TNM classification because the TNM system had multiple versions in the SEER database and did not apply to all patients [26]. Furthermore, considering its strong invasion ability and unique pathological characteristics limiting the surgical options, SCLC was not included in the present study [27, 28]. Although LCNEC has been found to harbor subpopulations of tumors with SCLC, surgery should be offered to medically fit patients with both early and locally advanced LCNEC [29-31]. Therefore, we enrolled patients with LCNEC in this study. Patients were excluded who (1) aged < 18 years; (2) had a diagnosis of any other cancer; (3) did not undergo radical surgery with systematic LN dissection; (4) had the diagnosis lacking pathological evidence; (5) were at pN0/pN3 disease; (6) had distant metastasis (M1);

(7) received preoperative radiotherapy; (8) survived less or equal to 30 days after surgery; (9) had missing data on race, laterality, tumor location, radiotherapy, TNM staging system, and survival outcomes.

2.3 Variable extraction, preparation, grouping, and calculation

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

The baseline demographics data including age at diagnosis (≤62 and >62), sex (male and female), and race (white, black, and other) were extracted from the SEER database. Data on baseline tumor-related characteristics included primary site (upper lobe, middle lobe, lower lobe, and other), laterality (right and left), histotypes (TC, AC, and LCNEC), tumor differentiation (well/moderately differentiated, poorly differentiated /undifferentiated, and unknown), T classification (T1, T2, T3, and T4), and N classification (N1 and N2). In addition, treatment information including surgical intervention (sublobectomy, lobectomy, and pneumonectomy), radiotherapy (yes and no/unknown), chemotherapy (yes and no/unknown), NDLN, and NPLN was also extracted from the **LODDS** calculated database. was as: $LODDS = log \frac{NPLN + 0.50}{NDLN - NPLN + 0.5}$. To avoid an infinite number, 0.50 was added to both the numerator and denominator. Lung cancer-specific survival (CSS) and overall survival (OS) were two of the study endpoints. The period from diagnosis to all-cause death was referred to as OS, while the time from diagnosis to LNET-related death was referred to as CSS. For censored data, the follow-up duration was computed as the number of months between diagnosis and death or the last follow-up (December 31, 2016).

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

2.4 Statistical analysis strategy Baseline characteristics of study cohort stratified by LODDS were compared by using Student t test, Mann-Whitney test, Pearson's χ^2 test, or Fisher's exact test as appropriate. Continuous variables were displayed with the mean (standard deviation [SD]) or the median (interquartile range [IQR]), while categorical variables were reported as count and percentages. First, we analyzed LODDS as a continuous variable. A smooth curve was drawn to estimate the association between LODDS and its hazard ratios (HRs) using restricted cubic spline regression analysis according to the method of Chen et al [32]. Second, we took LODDS as a categorical variable. LODDS was dichotomized via the X-tile software [33]. Survival curves were calculated using the Kaplan-Meier method and compared using the log-rank test. To assess the connection between LODDS and each study outcome, a multivariable Cox proportional-hazards regression model was used, controlling for relevant confounders. These confounders were selected based on their associations with the study endpoints of interest or a change in effect estimate of over 10%. The relatively low LODDS group was used as a reference group, and the results are presented as HRs with 95% confidence intervals (CIs). Third, a series of subgroup analyses were performed according to age at diagnosis, sex, primary site, laterality, histotypes, tumor differentiation, T classification, and N classification. All statistical analyses were performed using R software (version.3.6.14.1.0; The R Project for Statistical Computing, TX, USA; http://www.r-project.org) and

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

EmpowerStats (version 2.0; http://www.empowerstats.com). Two-tailed P < 0.050was deemed as statistical significance. 2.5 Construction and validation of nomograms Patients with purchased/referred care delivery areas (PRCDA) of East, Northern plains, and Alaska were regarded as the derivation cohort, while the external validation cohort includes patients with PRCDA of Pacific coast and Southwest. StepAIC algorithm was used in multivariable Cox regression analysis to select the predictors for the final models [34]. Using these identified prognostic factors, we constructed two nomograms for predicting 1-, 3-, and 5-year CSS and OS in LNET patients. Several indexes and methods were used to assess the accuracy of our nomograms. First, Harrell's concordance index (c-index) was calculated to quantify the discrimination performance of the nomograms. Second, a calibration curve, which is a diagram presenting the association between predicted probabilities and actual survival rate at 1, 3, and 5 years, along with a bootstrapped sample of the study cohort, was used to assess the calibration. Third, a comparison between our nomogram and the conventional eighth edition of the TNM staging system was conducted by calculating integrated discrimination improvement (IDI) and net reclassification improvement (NRI) [35]. Z test was used to examine the difference. Fourth, the decision curve analysis (DCA) was performed to test the clinical usefulness of the nomograms and TNM classification. Finally, to facilitate researchers' and clinicians' usage of our

model, we created two user-friendly webservers for our nomograms.

3. Results

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

3.1 Patients characteristics and cutoff value for LOODS

The SEER database collected 11,870 patients diagnosed with LNETs from January 2004 to December 2015. After employing the inclusion and exclusion criteria, 506 patients remained in the final study cohort. The selection process were summarized in Figure 1. Based on the results calculated by the X-tile software, the optimal cutoff value of LODDS was set as -0.33. Therefore, the study cohort was dichotomized into the low LODDS group (-1.44≤LODDS<-0.33; n=334) and the high LODDS group (-0.33≤LODDS≤1.14; n=172). Baseline demographic and clinicopathological features of participants stratified by LODDS were listed in Table 1. The median number of NDLN was 12.00 (IQR: 8.00-17.00) in the low LODDS group and 5.00 (IQR: 3.00-9.00) in the high LODDS group, whereas the median number of NPLN was 1.00 (IQR: 1.00-2.00) in the low LODDS group and 2.00 (IQR: 1.00-4.00) in the high LODDS group. Compared with the low LODDS group (-1.44≤LODDS<-0.33), the patients included in the high LODDS group (-0.33≤LODDS≤1.14) were more likely to be diagnosed in the N2 classification (P < 0.001), have more positive lymph nodes (P < 0.001) and receive radiotherapy (P=0.045). No difference was observed in age at diagnosis, sex, race, laterality, tumor site, histotype, differentiation, T classification, surgery, and chemotherapy between the two cohorts (all P-values > 0.050).

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

3.2 Restricted cubic spline analysis We performed a common Cox regression analysis using LODDS as a continuous variable and found the adjusted HRs of LODDS for CSS and OS were 2.21 (95% CI: 1.52-3.20, P<0.001) and 1.51 (95%CI: 1.10-2.06, P=0.010). Second, two piece-wise Cox regression analyses were conducted and the inflection points were found (-0.27) for CSS, -0.26 for OS, Table S1). For the LODDS < -0.27, every 1 increase in LODDS was associated with a 321% increase in CSS (P<0.001), while for the LODDS > -0.27, every 1 increase in LODDS was associated with a 24% increase in CSS (P=0.555). For a LODDS < -0.26, every 1 increase in LODDS was associated with a 135% increase in OS (P<0.001), while for a LODDS > -0.26, every 1 increase in LODDS was associated with a 4% decrease in OS (P=0.906). As shown in the restricted cubic spline analyses (Figure 2), the HRs for LODDS as a continuous variable tends to show a saturation effect. 3.3 Survival analysis The median follow-up time for the entire cohort was 42 months (IQR, 19-77 months). A total of 180 (35.57%) patients died from any cause, and 135 (26.68%) patients died from LNET-related death at the end of the study period. The cumulative 1-, 3-, and 5-year CSS and OS rates for patients stratified by LODDS were summarized in *Tables* S2. The survival curves showed that patients with the higher values of LODDS (-0.33) \leq LODDS \leq 1.14) were associated with worse prognosis (log-rank test: P=0.001 for CSS; P=0.005 for OS, Figures S1). Based on the entire cohort, the univariable Cox regression model suggested that age at diagnosis, race, site, histotype, differentiation,

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

T classification, N classification, surgery, radiotherapy, chemotherapy, and LODDS were all significant variables for CSS in *Table S3*. The multivariable Cox regression analysis demonstrated that participants in the high LODDS group (-0.33≤LODDS≤ 1.14) was related to reducing survival compared to those in the low LODDS group (-1.44≤LODDS<-0.33) (HR=2.06, 95% CI: 1.43-2.97, P<0.001) (Table 2 and Table S3). The multivariable Cox regression analysis for OS yielded similar results (HR=1.66, 95% CI: 1.22-2.26, P=0.001, **Table 2 and Table S4**). To eliminate the potential bias caused by the LN fragments, we performed a sensitivity analysis by restricting the resected LN count to fewer than or equal to 20, and found that LODDS remained statistically significant (CSS: HR=2.16, 95% CI: 1.46-3.19, P<0.001; OS: HR=1.75, 95% CI: 1.25-2.43, P=0.001) (Table 2 and Table S5-6). Furthermore, the extent of LN management should be in accordance with the IASLC recommendations, which involves a minimum of 6 nodes/stations, therefore we excluded patients with the examined LN count to fewer than 6. The multivariable Cox regression analysis yielded similar results (CSS: HR=2.84, 95% CI: 1.78-4.50, P<0.001; OS: HR=2.37, 95% CI: 1.59-3.54, *P*<0.001) (*Table 2 and Table S7-8*). 3.4 Subgroup analysis For CSS, subgroup analyses showed the higher LODDS (-0.33≤LODDS≤1.14) was also associated with deteriorative mortality in most strata (*Table S9*). Even among patients with the same N stage, LODDS still could distinguish and stratify patients into different risk groups. (N1 stage subgroup: HR=1.99, 95% CI: 1.14-3.45, *P*=0.015; N1 stage subgroup: HR=2.24, 95% CI: 1.27-3.96, *P*=0.006). For OS, in the N1 stage subgroup, the HR remained the trend of increase despite the results were not statistically significant (HR=1.56, 95% CI: 0.98-2.49, *P*=0.060).

3.5 Construction and validation of the nomogram

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

Prognostic nomograms for CSS and OS were established including significant indicators selected by StepAIC algorithm in multivariable Cox regression analysis. For nomogram construction and validation, among the final study cohort including 506 patients, 300 of them were assigned to the derivation cohort (PRCDA=East, Northern plains, and Alaska) and 206 of them were assigned to the validation cohort (PRCDA=Pacific coast, Southwest). The comparison of baseline characteristics between the derivation cohort and validation cohort was summarized in *Table S10*. No difference was observed in most variables except sex. The nomogram of CSS showed that histotype contributed the most to the prognosis, followed by age at diagnosis, LODDS, surgery, and chemotherapy (Fig 3 and Table 3). Similarly, the nomogram of OS showed that histotype contributed the most to the prognosis, followed by age at diagnosis, chemotherapy, LODDS, and radiotherapy (Fig 3 and **Table 4**). The top point reference scale of the nomograms assigned a score for each category of these predictive variables. After adding up the total score and locating the sum on the total points reference scale, a straight line was drawn to the bottom survival probability scale to find the estimated 1-/3-/5- survival rate.

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

The nomogram was validated internally in the derivation cohort and externally in the validation cohort. C-indexes of CSS for derivation cohort and validation cohort were 0.845 (0.804-0.886), and 0.821 (0.771-0.871). C-indexes of OS for derivation cohort and validation cohort were 0.821 (0.783-0.858), and 0.811 (0.766-0.856). Additionally, the calibration plots (Fig 4) revealed that the points were close to the 45-degree line, indicating a good similarity between the nomogram-predicted and actual survival states. 3.6 Comparison of the nomogram and the eighth edition TNM staging system The comparisons between the nomograms and the TNM staging system were also performed (*Table S11*). Analysis of accuracy showed that the NRI for the 1-, 3-, and 5-year CSS were 0.721 (95% CI: 0.825-0.554, P<0.001), 0.645 (95% CI: 0.743-0.414, P<0.001) and 0.627 (95% CI: 0.768-0.403, P<0.001) in the validation cohorts, respectively. Similarly, in the validation set, the IDI for 1-, 3-, and 5-years CSS were 0.249 (95% CI: 0.389-0.161, P<0.001), 0.391 (95% CI: 0.519-0.243, P<0.001), and 0.42 (95% CI: 0.537-0.265, P<0.001), respectively. Furthermore, the DCA curve was applied to determine the clinical applicability of the nomogram and TNM staging system. The DCA curves showed that our nomograms were better than the TNM staging system, as it added more net benefits compared with the TNM classification for almost all threshold probabilities based on the derivation cohort and validation cohort (Fig S2 and S3).

3.7 Development of webservers for convenient clinical use

Two dynamic, visualized and publicly accessible online nomograms based on the multivariable Cox regression models were built (CSS: https://drboidedwater.shinyapps.io/DynNom-CSS-lungneuroendocrinecarcinoma/; OS: https://drboidedwater.shinyapps.io/DynNom-OS-lungneuroendocrinecarcinoma/) (*Fig S4*). The webservers may generate estimated survival probability and Kaplan-Meier

4. Discussion

curves by entering the covariates.

LNETs constitute a unique clinical subgroup of primary pulmonary tumors. Due to their relatively low incidence, no specific staging system exists for LNETs. An exact and reasonable assessment of the lymph node status plays a crucial role in the staging and prognosis evaluation of patients with LNCTs. In this study, we found that LODDS was independently associated with long-term clinical outcomes among patients with resectable LNETs. These results were robust to restricted cubic spline analysis and a series of sensitivity analyses. Second, we constructed a visualized and publicly accessible online nomogram, incorporating LODDS and routinely available demographic, staging and treatment information, to predict the survival probability for individual LNET patients. To our knowledge, the present study is the first to explore the prognostic value of LODDS for LNET based on a multi-center cohort with a relatively large sample size.

The involvement of regional lymph nodes in malignancies has been considered as

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

one of the most important prognostic factors. The eighth edition of the AJCC/UICC staging system of NSCLC classified metastasis to ipsilateral peribronchial and/or hilar nodes and intrapulmonary nodes as N1 classification, and metastasis into ipsilateral mediastinal and/or subcarinal nodes into N2 classification, without taking into account numbers of examined and metastatic lymph nodes [36]. LODDS is a new LN ratio-based index and has been identified as an independent predictor in many malignancies such as rectal cancer [37], pancreatic cancer [38], gallbladder cancer [39], gastric cancer [40], and colon cancer [41]. Recently, several studies were attempting to explore the prognostic value of LODDS for NSCLC. In 2020, we did a research and found that the high value of LODDS > -0.37 was independently associated with worse survival in patients with node-positive lung squamous cell carcinoma [20]. Dziedzic et al. [19] found that it is possible to discriminate NSCLC patients more effectively by using LODDS compared to conventional N classification. Deng et al. [18] found LODDS and lymph node ratio (LNR) staging schemes outperformed those of NPLN for predicting OS and CSS among patients with node-positive NSCLC. However, most previous studies only focused on NSCLC, and few reports have explored the prognostic value of LODDS in LNETs. In the current study, either as a continuous or as a categorical variable, the high value of LODDS was associated with worse survival for N1/N2 stage patients with LNETs. However, LODDS must be used and calculated with caution, because the value of LODDS is influenced by the number of dissected LN. Therefore, a series of sensitivity analyses were performed. For LNETs, the extent of LN management

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

should conform to the International Association for the Study of Lung Cancer (IASLC) recommendations, which involves a minimum of 6 nodes/stations, 3 of which should be mediastinal including the subcarinal station [42]. Considering that the accurate value of LODDS was dependent on the adequate NDLN, we excluded patients with examined LN count less than 6 and found that LODDS could still serve as an independent predictor for LNETs. In addition, it is quite easy to damage the integrity of the LN during surgery, especially when the LNs are adhesive to each other or difficult to be separated from the dissected tissues [43]. To avoid the potential bias led by fragmented LNs, we excluded patients with examined LN count of more than 20, the results did not change. Furthermore, in the subgroup stratified by different N stages (N1 and N2 stages), LODDS could still discriminate the high-risk population from the low-risk one. Additionally, to our surprise, N classification was excluded from our nomograms. The possible reason is that the anatomical definition of LN station is more complicated and dependent on surgery quality, which thus might potentially cause misclassification of the stage, and thus be replaced by LODDS [44, 45]. In summary, LODDS is the ratio-based LN staging system that combines NPLN and NNLN, which might be superior to some number-based LN assessment methods. Furthermore, in LODDS, the numerator and denominator are both added with a value of 0.5, eliminating the singularities caused by null data, therefore LODDS might be used to estimate survival of node-negative patients, as opposed to LNR.

The LODDS was not the only prognostic factor included in our nomogram.

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

Similar to previous studies [46-48], age at diagnosis, histotype, surgery, radiotherapy, and chemotherapy were independent prognostic factors of CSS or OS. In this study, the nomogram showed that histotype contributed the most to the prognosis, which indicated tumor histotype is a crucial determinant of the clinical behavior of LNETs. Our nomogram indicated that LCNEC showed the worst prognosis followed by AC and TC. Growing evidence also suggests that high-grade LCNEC is biologically distinct from low-grade TC and intermediate-grade AC in view of clinical behavior, pathologic features, molecular alterations as well as possible precursor lesions [49]. All-stage 5-year OS for LCNEC fluctuated between 13% and 57% [50]. Different from LCNEC, TC and AC are more commonly found in younger patients without smoking histories. AC is significantly more aggressive than TC, with a higher frequency of nodal and distant metastases, and 5-year survival of 60%. In this study, we did not include SCLC patients, because a unique feature of SCLC is that it is generally considered a nonsurgical disease [51]. The optimal type of surgical treatment for LNETs is controversial. The surgical approach depends on tumor size, location, and preoperative biopsy specimen assessment. Several studies reported that wedge resection may increase the risk of tumor recurrences, especially in node-positive TC or AC [52, 53]. Lobectomy is reported as superior to segmentectomy in terms of OS in some, but not all in pulmonary carcinoids [54-56]. Similar to these studies, our study showed that lobectomy was superior to sublobectomy and pneumonectomy in the nomogram for CSS. Furthermore, there is an absence of high-quality evidence to show whether or

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

not chemotherapy could provide clinical benefits for LNETs. Although our nomogram showed that chemotherapy might be associated with more favorable prognoses. However, the results need to be interpreted with caution. In the SEER database, patients without receiving chemotherapy and those with unknown information about adjuvant therapy were classified into one category, which might lead to potential bias. Until now, for pulmonary carcinoids, routine adjuvant therapy may only be considered in selected fit patients (AC, N2 stage) with a particularly high risk of relapse [57]. Besides, Iyoda et al. [58] suggested that platinum-based adjuvant chemotherapy after surgery could help patients with LCNEC prevent recurrence. Because LNET is a heterogeneous disease, each LNET patient requires an individualized and timely risk assessment, which allows for more precise therapeutic strategies and medical resource allocation decisions. In this study, we developed and validated a nomogram to predict prognosis in patients with LNET. Our nomograms based on LODDS were more accurate and obtained more clinical net benefit than the conventional AJCC/UICC TNM staging system. In summary, the online nomograms, composed of several easily obtained predictors, could be a simpler way to engage clinicians in death risks, patient counseling, and decision-making. To put it another way, LNET patients with poorer clinical results estimated by nomograms may require more aggressive therapy. [28]. Several limitations of this study should be noted. First, the SEER database lacks some detailed data, such as smoking history, some promising molecular markers (e.g. Ki-67), imaging techniques used before surgery, histological and morphological data

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

(e.g. mitotic rate), type of resection (R0, R1, or R2), and use of systemic therapies. Therefore they could not be included as covariables in the multivariable Cox models. Second, information about postoperative comorbidities, and tumor recurrence is also not available in the database. Third, although we reclassified the TNM classification according to the eighth edition of AJCC/UICC TNM classification, the TNM staging system, which was derived from the SEER database's collaborative stage system, is a combination of clinical and pathologic stages. Because of the distinction between clinical and pathologic stages, more subgroup analysis is required when using a single clinical or pathologic staging system. 5. Conclusions LODDS was found to be useful in predicting survival outcomes in LNET patients who underwent surgery. Online dynamic nomograms including LODDS to evaluate CSS and OS were constructed. The well-executed nomograms may aid clinicians in providing reasonable, customized therapeutic strategies for LNET patients. **Funding support** This study was funded by Development Fund for the Department of Anesthesiology of Shanghai Pulmonary Hospital. The funders have no role in the study design, data collection, data analysis and completion of the manuscripts.

Conflict of interest disclosures

There are no conflicts of interest with any of the authors.

CRediT authorship contribution statement

- 464 Suyu Wang and Yue Yu: Conceptualization, Methodology, Software, Investigation,
- Writing-original draft, Writing-review & editing. Juan Wei: Software, Data curation,
- 466 Investigation, Writing-original draft. Yibin Guo and Qiumeng Xu: Visualization,
- 467 Investigation. Xin Lv: Software, Validation. Meiyun Liu: Funding acquisition,
- 468 Writing-review & editing.

461

462

463

469

470


References

- 471 [1] Hendifar AE, Marchevsky AM and Tuli R. Neuroendocrine Tumors of the Lung: Current
- Challenges and Advances in the Diagnosis and Management of Well-Differentiated Disease. J
- 473 Thorac Oncol 2017; 12: 425-436.
- 474 [2] Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T and Yao JC. Trends in the Incidence,
- Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United
- 476 States. JAMA Oncol 2017; 3: 1335-1342.
- 477 [3] Hallet J, Law CH, Cukier M, Saskin R, Liu N and Singh S. Exploring the rising incidence of
- neuroendocrine tumors: a population-based analysis of epidemiology, metastatic
- presentation, and outcomes. Cancer 2015; 121: 589-597.
- 480 [4] Naalsund A, Rostad H, Strøm EH, Lund MB and Strand TE. Carcinoid lung tumors--incidence,
- treatment and outcomes: a population-based study. Eur J Cardiothorac Surg 2011; 39:
- 482 565-569.
- 483 [5] Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S,
- Duhig E, Flieder DB, Geisinger K, Hirsch FR, Ishikawa Y, Kerr KM, Noguchi M, Pelosi G, Powell
- 485 CA, Tsao MS and Wistuba I. The 2015 World Health Organization Classification of Lung
- 486 Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J
- 487 Thorac Oncol 2015; 10: 1243-1260.
- 488 [6] Yoon JY, Sigel K, Martin J, Jordan R, Beasley MB, Smith C, Kaufman A, Wisnivesky J and Kim
- 489 MK. Evaluation of the Prognostic Significance of TNM Staging Guidelines in Lung Carcinoid
- 490 Tumors. J Thorac Oncol 2019; 14: 184-192.
- 491 [7] Yeh YC and Chou TY. Pulmonary neuroendocrine tumors: study of 90 cases focusing on
- 492 clinicopathological characteristics, immunophenotype, preoperative biopsy, and frozen
- 493 section diagnoses. J Surg Oncol 2014; 109: 280-286.
- 494 [8] Robelin P, Hadoux J, Forestier J, Planchard D, Hervieu V, Berdelou A, Scoazec JY, Valette PJ,

495		Leboulleux S, Ducreux M, Lombard-Bohas C, Baudin E and Walter T. Characterization,
496		Prognosis, and Treatment of Patients With Metastatic Lung Carcinoid Tumors. J Thorac Oncol
497		2019; 14: 993-1002.
498	[9]	Filosso PL, Oliaro A, Ruffini E, Bora G, Lyberis P, Asioli S, Delsedime L, Sandri A and Guerrera F.
499		Outcome and prognostic factors in bronchial carcinoids: a single-center experience. J Thorac
500		Oncol 2013; 8: 1282-1288.
501	[10]	Aydin E, Yazici U, Gulgosteren M, Agackiran Y, Kaya S, Gulhan E, Tastepe I and Karaoglanoglu N.
502		Long-term outcomes and prognostic factors of patients with surgically treated pulmonary
503		carcinoid: our institutional experience with 104 patients. Eur J Cardiothorac Surg 2011; 39:
504		549-554.
505	[11]	Kodera Y, Yamamura Y, Shimizu Y, Torii A, Hirai T, Yasui K, Morimoto T, Kato T and Kito T. The
506		number of metastatic lymph nodes: a promising prognostic determinant for gastric
507		carcinoma in the latest edition of the TNM classification. J Am Coll Surg 1998; 187: 597-603.
508	[12]	Sinn HP, Helmchen B and Wittekind CH. [TNM classification of breast cancer: changes and
509		comments on the 7th edition]. Pathologe 2010; 31: 361-366.
510	[13]	Gallegos-Hernandez JF, Hernandez-Hernandez DM, Flores-Diaz R, Sierra-Santiesteban I,
511		Pichardo-Romero P, Arias-Ceballos H, Minauro-Munoz G and Alvarado-Cabrero I. The number
512		of sentinel nodes identified as prognostic factor in oral epidermoid cancer. Oral Oncol 2005;
513		41: 947-952.
514	[14]	Yang L, Xiong Z, Xie Q, He W, Liu S, Kong P, Jiang C, Guo G and Xia L. Prognostic value of total
515		number of lymph nodes retrieved differs between left-sided colon cancer and right-sided
516		colon cancer in stage patients with colon cancer. BMC Cancer 2018; 18: 558.
517	[15]	Chu X and Yang ZF. Impact on survival of the number of lymph nodes resected in patients
518		with lymph node-negative gastric cancer. World J Surg Oncol 2015; 13: 192.
519	[16]	Tsim S, O'Dowd CA, Milroy R and Davidson S. Staging of non-small cell lung cancer (NSCLC): a
520		review. Respir Med 2010; 104: 1767-1774.
521	[17]	Lv P, Chen G and Zhang P. Log odds of positive lymph nodes are superior to other measures
522		for evaluating the prognosis of non-small cell lung cancer. Thorac Cancer 2014; 5: 570-575.
523	[18]	Deng W, Xu T, Wang Y, Xu Y, Yang P, Gomez D and Liao Z. Log odds of positive lymph nodes
524		may predict survival benefit in patients with node-positive non-small cell lung cancer. Lung
525		Cancer 2018; 122: 60-66.
526	[19]	Dziedzic D, Piotr R, Langfort R and Orlowski T. Log odds of positive lymph nodes as a novel
527		prognostic indicator in NSCLC staging. Surg Oncol 2017; 26: 80-85.
528	[20]	Yu Y, Zhang P, Yao R, Wang J, Wang P, Xue X, Xiao J and Wang Z. Prognostic value of log odds
529		of positive lymph nodes in node-positive lung squamous cell carcinoma patients after surgery:
530		a SEER population-based study. Transl Lung Cancer Res 2020; 9: 1285-1301.
531	[21]	Wang S, Yu Y, Xu W, Lv X, Zhang Y and Liu M. Dynamic nomograms combining N classification
532		with ratio-based nodal classifications to predict long-term survival for patients with lung
533		adenocarcinoma after surgery: a SEER population-based study. BMC Cancer 2021; 21: 653.
534	[22]	Yu Y, Huang R, Wang P, Wang S, Ling X, Zhang P, Yu J, Wang J, Xiao J and Wang Z.
535		Sublobectomy versus lobectomy for long-term survival outcomes of early-stage non-small cell
536		lung cancer with a tumor size ≤2 cm accompanied by visceral pleural invasion: a SEER
537		population-based study. J Thorac Dis 2020; 12: 592-604.

538 539	[23]	Collins GS, Reitsma JB, Altman DG and Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. Bmj
540		2015; 350: g7594.
541 542	[24]	Cronin KA, Ries LA and Edwards BK. The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute. Cancer 2014; 120 Suppl 23: 3755-3757.
543	[25]	Goodyear MD, Krleza-Jeric K and Lemmens T. The Declaration of Helsinki. Bmj 2007; 335:
544		624-625.
545	[26]	Detterbeck FC. The eighth edition TNM stage classification for lung cancer: What does it
546		mean on main street? J Thorac Cardiovasc Surg 2018; 155: 356-359.
547	[27]	Jackson AS, Rosenthal A, Cattoni M, Bograd AJ, Farivar AS, Aye RW, Vallières E and Louie BE.
548		Staging System for Neuroendocrine Tumors of the Lung Needs to Incorporate Histologic
549		Grade. Ann Thorac Surg 2020; 109: 1009-1018.
550	[28]	Yi C, Dai J, Song N, Wu C, Zhang L, Zhu Y, Jiang G, Zhang H and Zhang P. Improvement of
551		pathological staging system for neuroendocrine tumors of the lung. Ann Transl Med 2021; 9:
552		447.
553	[29]	Iyoda A, Makino T, Koezuka S, Otsuka H and Hata Y. Treatment options for patients with large
554		cell neuroendocrine carcinoma of the lung. Gen Thorac Cardiovasc Surg 2014; 62: 351-356.
555	[30]	lyoda A, Azuma Y and Sano A. Neuroendocrine tumors of the lung: clinicopathological and
556		molecular features. Surg Today 2020; 50: 1578-1584.
557	[31]	Raman V, Jawitz OK, Yang CJ, Voigt SL, Tong BC, D'Amico TA and Harpole DH. Outcomes for
558		Surgery in Large Cell Lung Neuroendocrine Cancer. J Thorac Oncol 2019; 14: 2143-2151.
559	[32]	Chen S, Honda T, Ohara T, Hata J, Hirakawa Y, Yoshida D, Shibata M, Sakata S, Oishi E, Furuta Y,
560		Kitazono T and Ninomiya T. Serum homocysteine and risk of dementia in Japan. J Neurol
561		Neurosurg Psychiatry 2020; 91: 540-546.
562	[33]	Camp RL, Dolled-Filhart M and Rimm DL. X-tile: a new bio-informatics tool for biomarker
563		assessment and outcome-based cut-point optimization. Clin Cancer Res 2004; 10: 7252-7259.
564	[34]	Jungk C, Reinhardt A, Warta R, Capper D, Deimling AV, Herold-Mende C and Unterberg A.
565		Extent of Resection, MGMT Promoter Methylation Status and Tumor Location Independently
566		Predict Progression-Free Survival in Adult Sporadic Pilocytic Astrocytoma. Cancers (Basel)
567		2019; 11:
568	[35]	Vickers AJ and Elkin EB. Decision curve analysis: a novel method for evaluating prediction
569		models. Med Decis Making 2006; 26: 565-574.
570	[36]	Taylor MD, LaPar DJ, Thomas CJ, Persinger M, Stelow EB, Kozower BD, Lau CL and Jones DR.
571		Lymph node ratio predicts recurrence and survival after RO resection for non-small cell lung
572		cancer. Ann Thorac Surg 2013; 96: 1163-1170.
573	[37]	Huang B, Ni M, Chen C, Cai G and Cai S. LODDS is superior to lymph node ratio for the
574		prognosis of node-positive rectal cancer patients treated with preoperative radiotherapy.
575		Tumori 2017; 103: 87-92.
576	[38]	Ramacciato G, Nigri G, Petrucciani N, Pinna AD, Ravaioli M, Jovine E, Minni F, Grazi GL,
577		Chirletti P, Tisone G, Ferla F, Napoli N and Boggi U. Prognostic role of nodal ratio, LODDS, pN
578		in patients with pancreatic cancer with venous involvement. BMC Surg 2017; 17: 109.
579	[39]	Xiao Z, Shi Z, Hu L, Gao Y, Zhao J, Liu Y, Xu Q and Huang D. A new nomogram from the SEER
580		database for predicting the prognosis of gallbladder cancer patients after surgery. Ann Transl

Med 2019; 7: 738.



Multi-centric Study of Neuroendocrine Tumours of the Lung. Eur J Cardiothorac Surg 2007; 31:

25

626		192-197.
627	[54]	Filosso PL, Rena O, Guerrera F, Moreno Casado P, Sagan D, Raveglia F, Brunelli A, Welter S,
628		Gust L, Pompili C, Casadio C, Bora G, Alvarez A, Zaluska W, Baisi A, Roesel C and Thomas PA.
629		Clinical management of atypical carcinoid and large-cell neuroendocrine carcinoma: a
630		multicentre study on behalf of the European Association of Thoracic Surgeons (ESTS)
631		Neuroendocrine Tumours of the Lung Working Group†. Eur J Cardiothorac Surg 2015; 48:
632		55-64.
633	[55]	Steuer CE, Behera M, Kim S, Chen Z, Saba NF, Pillai RN, Owonikoko TK, Khuri FR and
634		Ramalingam SS. Atypical carcinoid tumor of the lung: a surveillance, epidemiology, and end
635		results database analysis. J Thorac Oncol 2015; 10: 479-485.
636	[56]	Marciello F, Mercier O, Ferolla P, Scoazec JY, Filosso PL, Chapelier A, Guggino G, Monaco R,
637		Grimaldi F, Pizzolitto S, Guigay J, de Latour BR, Giuffrida D, Longchampt E, de Montpreville VT,
638		Fadel E, Colao A, Planchard D, Papotti M, Faggiano A and Baudin E. Natural History of
639		Localized and Locally Advanced Atypical Lung Carcinoids after Complete Resection: A Joined
640		French-Italian Retrospective Multicenter Study. Neuroendocrinology 2018; 106: 264-273.
641	[57]	Baudin E, Caplin M, Garcia-Carbonero R, Fazio N, Ferolla P, Filosso PL, Frilling A, de Herder
642		WW, Hörsch D, Knigge U, Korse CM, Lim E, Lombard-Bohas C, Pavel M, Scoazec JY, Sundin A
643		and Berruti A. Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis,
644		treatment and follow-up(☆). Ann Oncol 2021; 32: 439-451.
645	[58]	Iyoda A, Hiroshima K, Moriya Y, Takiguchi Y, Sekine Y, Shibuya K, Iizasa T, Kimura H, Nakatani Y
646		and Fujisawa T. Prospective study of adjuvant chemotherapy for pulmonary large cell
647		neuroendocrine carcinoma. Ann Thorac Surg 2006; 82: 1802-1807.
648		

Tables 1-4

Table 1. Baseline characteristics of the entire dataset stratified by LODDS

Characteristic	Total	-1.44≤LODDS<-0.33	-0.33≤LODDS≤1.14	P value*
Omnucionale.	(n=506)	(n=334)	(n=172)	
Age at diagnosis (year)				0.183
≤62	300 (59.29)	205 (61.38)	95 (55.23)	
>62	206 (40.71)	129 (38.62)	77 (44.77)	
Sex				0.979
Male	232 (45.85)	153 (45.81)	79 (45.93)	
Female	274 (54.15)	181 (54.19)	93 (54.07)	
Race				0.63
White	453 (89.53)	302 (90.42)	151 (87.79)	
Black	29 (5.73)	17 (5.09)	12 (6.98)	
Other	24 (4.74)	15 (4.49)	9 (5.23)	
Laterality				0.639
Right	281 (55.53)	183 (54.79)	98 (56.98)	
Left	225 (44.47)	151 (45.21)	74 (43.02)	
Site				0.767
Upper lobe	194 (38.34)	131 (39.22)	63 (36.63)	
Middle lobe	64 (12.65)	39 (11.68)	25 (14.53)	
Lower lobe	196 (38.74)	131 (39.22)	65 (37.79)	
Other	52 (10.28)	33 (9.88)	19 (11.05)	
Histotype				0.395
Large cell neuroendocrine carcinoma	129 (25.49)	82 (24.55)	47 (27.33)	

Carcinoid tumor	274 (54.15)	188 (56.29)	86 (50.00)	
Atypical carcinoid tumor	103 (20.36)	64 (19.16)	39 (22.67)	
Differentiation				0.710
Well/moderately differentiated	201 (39.72)	136 (40.72)	65 (37.79)	
Poorly differentiated /undifferentiated	97 (19.17)	65 (19.46)	32 (18.60)	
Unknown	208 (41.11)	133 (39.82)	75 (43.60)	
T classification				0.409
T1	209 (41.30)	131 (39.22)	78 (45.35)	
T2	190 (37.55)	134 (40.12)	56 (32.56)	
T3	74 (14.62)	48 (14.37)	26 (15.12)	
T4	33 (6.52)	21 (6.29)	12 (6.98)	
N classification				< 0.001
N1	319 (63.04)	230 (68.86)	89 (51.74)	
N2	187 (36.96)	104 (31.14)	83 (48.26)	
Surgery				0.051
Sublobectomy	44 (8.70)	22 (6.59)	22 (12.79)	
Lobectomy	406 (80.24)	272 (81.44)	134 (77.91)	
Pneumonectomy	56 (11.07)	40 (11.98)	16 (9.30)	
Radiotherapy				0.045
No	439 (86.76)	297 (88.92)	142 (82.56)	
Yes	67 (13.24)	37 (11.08)	30 (17.44)	
Chemotherapy				0.051
No	374 (73.91)	256 (76.65)	118 (68.60)	
Yes	132 (26.09)	78 (23.35)	54 (31.40)	
Number of dissected lymph nodes	9.00 (6.00-14.75)	12.00 (8.00-17.00)	5.00 (3.00-9.00)	< 0.001
Number of positive lymph nodes	2.00 (1.00-3.00)	1.00 (1.00-2.00)	2.00 (1.00-4.00)	< 0.001

LODDS as a continuous variable	-0.49 (-0.790.22)	-0.70 (-0.880.52)	0.00 (-0.22-0.20)	< 0.001
--------------------------------	-------------------	-------------------	-------------------	---------

[†]Data are listed as median (IQR) or n (%).*P values for Mann-Whitney test or Chi square test by comparing the basic characteristics in the two categorical LODDS groups.

[‡]LODDS, log odds of positive lymph node.

Table 2. HRs for multivariable analysis

	CSS		os		
Cohort	HR (95%CI)	P value	HR (95%CI)	P value	
Entire dataset					
Univariable analysis	1.73 (1.23-2.43)	0.002	1.52 (1.13-2.04)	0.006	
Multivariable analysis	2.06 (1.43-2.97)	< 0.001	1.66 (1.22-2.26)	0.001	
Patients with NDLN≤20					
Univariable analysis	1.89 (1.32-2.72)	0.001	1.65 (1.20-2.26)	0.002	
Multivariable analysis	2.16 (1.46-3.19)	< 0.001	1.75 (1.25-2.43)	0.001	
Patients with NDLN≥6					
Univariable analysis	2.16 (1.42-3.28)	< 0.001	1.97 (1.37-2.84)	< 0.001	
Multivariable analysis	2.84 (1.78-4.50)	< 0.001	2.37 (1.59-3.54)	< 0.001	

[†]CSS, cancer-specific survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; NDLN, number of dissected lymph node.

Table 3. Univariable and stepwise multivariable Cox proportional regression analysis for CSS of the derivation dataset

		Univariable analysis		Stepwise multivariable analysis	
Characteristic	N (%)	HR (95%CI)	P value	HR (95%CI)	P value
Age at diagnosis (year)					
≤62	172 (57.33)	1		1	
>62	128 (42.67)	2.92 (1.85-4.61)	< 0.001	2.16 (1.33-3.52)	0.002
Sex					
Male	132 (44.00)	1			
Female	168 (56.00)	0.68 (0.44-1.06)	0.087		
Race					
White	281 (93.67)	1			
Black	15 (5.00)	1.03 (0.38-2.81)	0.958		
Other	4 (1.33)	0 (0.00-Inf)	0.995		
Laterality					
Right	161 (53.67)	1			
Left	139 (46.33)	0.85 (0.54-1.32)	0.467		
Site					
Upper lobe	124 (41.33)	1			
Middle lobe	34 (11.33)	0.25 (0.09-0.71)	0.009		
Lower lobe	113 (37.67)	0.59 (0.36-0.96)	0.033		
Other	29 (9.67)	0.41 (0.16-1.04)	0.061		
Histotype					

Large cell neuroendocrine	86 (28.67)	1		1	
carcinoma				1	
Carcinoid tumor	152 (50.67)	0.08 (0.04-0.14)	< 0.001	0.06 (0.03-0.13)	< 0.001
Atypical carcinoid tumor	62 (20.67)	0.19 (0.10-0.35)	< 0.001	0.17 (0.09-0.33)	< 0.001
Differentiation					
Well/moderately differentiated	120 (40.00)	1			
Poorly differentiated	64 (21.33)	6.97 (3.87-12.52)	< 0.001		
/undifferentiated					
Unknown	116 (38.67)	1.52 (0.81-2.85)	0.195		
T classification					
T1	128 (42.67)	1			
T2	114 (38.00)	0.93 (0.56-1.54)	0.777		
T3	43 (14.33)	1.54 (0.82-2.88)	0.178		
T4	15 (5.00)	0.95 (0.34-2.68)	0.923		
N classification					
N1	193 (64.33)	1			
N2	107 (35.67)	1.74 (1.12-2.71)	0.014		
Surgery					
Sublobectomy	24 (8.00)	1		1	
Lobectomy	246 (82.00)	0.28 (0.15-0.52)	< 0.001	0.67 (0.34-1.31)	0.242
Pneumonectomy	30 (10.00)	0.45 (0.20-1.00)	0.049	1.27 (0.54-2.96)	0.588
Radiotherapy					
No	259 (86.33)	1			
Yes	41 (13.67)	2.34 (1.40-3.89)	0.001		
Chemotherapy					
No	214 (71.33)	1		1	

Yes	86 (28.67)	2.63 (1.69-4.10)	< 0.001	0.68 (0.4-1.15)	0.148
LODDS as a categorical variable					
-1.44≤LODDS<-0.33	197 (65.67)	1		1	
-0.33≤LODDS≤1.14	103 (34.33)	2.12 (1.36-3.29)	0.001	2.05 (1.28-3.29)	0.003

[†]CSS, cancer-specific survival; LODDS, log odds of positive lymph node; HR, hazard ratio; CI, confidence interval.

Table 4. Univariable and stepwise multivariable Cox proportional regression analysis for OS of the derivation dataset

		Univariable analysis		Stepwise multivariable analysis	
Characteristic	N (%)	HR (95%CI)	P value	HR (95%CI)	P value
Age at diagnosis (year)					
≤62	172 (57.33)	1		1	
>62	128 (42.67)	3.5 (2.36-5.20)	< 0.001	2.65 (1.75-4.01)	< 0.001
Sex					
Male	132 (44.00)	1			
Female	168 (56.00)	0.62 (0.43-0.91)	0.014		
Race					
White	281 (93.67)	1			
Black	15 (5.00)	1.11 (0.49-2.53)	0.801		
Other	4 (1.33)	0 (0.00-Inf)	0.994		
Laterality					
Right	161 (53.67)	1			
Left	139 (46.33)	0.87 (0.59-1.26)	0.453		
Site					
Upper lobe	124 (41.33)	1			
Middle lobe	34 (11.33)	0.41 (0.20-0.87)	0.020		
Lower lobe	113 (37.67)	0.74 (0.49-1.12)	0.149		
Other	29 (9.67)	0.69 (0.35-1.36)	0.284		
Histotype					

Large cell neuroendocrine	86 (28.67)	1			
carcinoma					
Carcinoid tumor	152 (50.67)	0.13 (0.08-0.20)	< 0.001	0.09 (0.05-0.16)	< 0.001
Atypical carcinoid tumor	62 (20.67)	0.23 (0.13-0.39)	< 0.001	0.19 (0.11-0.34)	< 0.001
Differentiation					
Well/moderately differentiated	120 (40.00)	1			
Poorly differentiated	64 (21.33)	6.22 (3.70-10.46)	< 0.001		
/undifferentiated					
Unknown	116 (38.67)	1.98 (1.18-3.34)	0.010		
T classification					
T1	128 (42.67)	1			
T2	114 (38.00)	1.12 (0.74-1.70)	0.586		
T3	43 (14.33)	1.35 (0.76-2.40)	0.301		
T4	15 (5.00)	0.91 (0.36-2.31)	0.849		
N classification					
N1	193 (64.33)	1			
N2	107 (35.67)	1.76 (1.21-2.57)	0.003		
Surgery					
Sublobectomy	24 (8.00)	1			
Lobectomy	246 (82.00)	0.38 (0.21-0.67)	0.001		
Pneumonectomy	30 (10.00)	0.49 (0.23-1.03)	0.058		
Radiotherapy					
No	259 (86.33)	1		1	
Yes	41 (13.67)	1.98 (1.26-3.12)	0.003	1.57 (0.9-2.72)	0.110
Chemotherapy					
No	214 (71.33)	1		1	

Yes LODDS as a categorical	86 (28.67)	1.86 (1.26-2.73)	0.002	0.44 (0.26-0.75)	0.003
variable -1.44≤LODDS<-0.33	197 (65.67)	1		1	
-0.33≤LODDS≤1.14	103 (34.33)	1.68 (1.15-2.45)	0.007	1.65 (1.12-2.42)	0.011

[†]LODDS, log odds of positive lymph node; OS, overall survival; HR, hazard ratio; CI, confidence interval.

Tables S1-11Table S1. HR for LODDS as a continuous variable

Model -	CSS			os		
Model	Piece-wise LODDS	HR (95%CI)	P value	Piece-wise LODDS	HR (95%CI)	P value
Cox regression model	-	2.21 (1.52-3.20)	< 0.001	-	1.51 (1.10-2.06)	0.010
Two piece-wise Cox regression model	LODDS<-0.27	4.21 (1.95-9.07)	< 0.001	LODDS<-0.26	2.35 (1.27-4.33)	0.006
model .	LODDS >-0.27	1.24 (0.60-2.55)	0.555	LODDS >-0.26	0.96 (0.51-1.82)	0.906

[†]HR for CSS were evaluated based on multivariable Cox proportional regression model adjusted by age, race, site, histotype, differentiation, T classification, N classification, surgery, radiotherapy and chemotherapy.

‡HR for OS were evaluated based on multivariable Cox proportional regression model adjusted by age, sex, site, histotype, differentiation, N classification, radiotherapy and chemotherapy.

§CSS, cancer-specific survival; LODDS, log odds of positive lymph node; OS, overall survival; HR, hazard ratio; CI, confidence interval.

Table S2. 1-, 3-, and 5-year CSS and OS of different LODDS subgroups

Cohort	-1.44≤LODDS<-0.33	-0.33≤LODDS≤1.14
1-year CSS (%)	93.83 (91.25-96.49)	87.52 (82.66-92.66)
3-year CSS (%)	83.92 (79.82-88.23)	70.57 (63.69-78.19)
5-year CSS (%)	76.83 (71.83-82.19)	62.09 (54.37-70.9)

1-year OS (%)	90.96 (87.93-94.1)	85.4 (80.28-90.86)
3-year OS (%)	78.7 (74.23-83.44)	66.22 (59.19-74.08)
5-year OS (%)	70.21 (64.94-75.91)	54.2 (46.46-63.23)

[†]CSS, cancer-specific survival; LODDS, log odds of positive lymph node; OS, overall survival.

Table S3 Univariable and multivariable Cox proportional regression analysis for the influence of LODDS on CSS of the entire dataset

Characteristic		Univariable analysis		Multivariable analysis	
	N (%) —	HR (95%CI)	P value	HR (95%CI)	P value
Age at diagnosis (year)					
≤62	300 (59.29)	1		1	
>62	206 (40.71)	2.81 (1.99-3.97)	< 0.001	2.25 (1.54-3.30)	< 0.001
Sex					
Male	232 (45.85)	1			
Female	274 (54.15)	0.80 (0.57-1.12)	0.200		
Race					
White	453 (89.53)	1		1	
Black	29 (5.73)	1.68 (0.91-3.12)	0.099	2.00 (1.02-3.92)	0.043
Other	24 (4.74)	0.98 (0.46-2.11)	0.964	0.70 (0.31-1.57)	0.389
Laterality					
Right	281 (55.53)	1			
Left	225 (44.47)	0.84 (0.60-1.18)	0.324		
Site					
Upper lobe	194 (38.34)	1		1	

Middle lobe	64 (12.65)	0.37 (0.19-0.75)	0.006	0.79 (0.37-1.67)	0.532
Lower lobe	196 (38.74)	0.70 (0.48-1.02)	0.062	0.89 (0.59-1.35)	0.594
Other	52 (10.28)	0.73 (0.40-1.33)	0.310	1.13 (0.54-2.35)	0.747
Histotype					
Large cell neuroendocrine	120 (25 40)	1		1	
carcinoma	129 (25.49)				
Carcinoid tumor	274 (54.15)	0.09 (0.06-0.14)	< 0.001	0.07 (0.04-0.14)	< 0.001
Atypical carcinoid tumor	103 (20.36)	0.27 (0.17-0.42)	< 0.001	0.23 (0.13-0.42)	< 0.001
Differentiation					
Grade I-II	201 (39.72)	1		1	
Poorly differentiated	97 (19.17)	7.20 (4.52-11.45)	< 0.001	1.52 (0.76-3.05)	0.235
/undifferentiated					
Unknown	208 (41.11)	1.72 (1.07-2.76)	0.025	1.29 (0.77-2.18)	0.335
T classification					
T1	209 (41.30)	1		1	
T2	190 (37.55)	0.89 (0.60-1.32)	0.555	0.72 (0.48-1.09)	0.117
Т3	74 (14.62)	1.66 (1.04-2.67)	0.035	0.89 (0.53-1.50)	0.673
T4	33 (6.52)	1.41 (0.74-2.70)	0.298	1.19 (0.57-2.50)	0.645
N classification					
N1	319 (63.04)	1		1	
N2	187 (36.96)	1.65 (1.18-2.32)	0.004	1.16 (0.79-1.70)	0.453
Surgery					
Sublobectomy	44 (8.70)	1		1	
Lobectomy	406 (80.24)	0.58 (0.34-0.98)	0.044	1.08 (0.60-1.93)	0.805
Pneumonectomy	56 (11.07)	1.04 (0.55-1.97)	0.894	2.01 (0.99-4.09)	0.054
Radiotherapy					

No	439 (86.76)	1		1	
Yes	67 (13.24)	2.05 (1.36-3.10)	0.001	1.05 (0.65-1.71)	0.847
Chemotherapy					
No	374 (73.91)	1		1	
Yes	132 (26.09)	2.38 (1.69-3.35)	< 0.001	0.50 (0.31-0.81)	0.005
LODDS as a categorica	l				
variable					
-1.44≤LODDS<-0.33	334 (66.01)	1		1	
-0.33≤LODDS≤1.14	172 (33.99)	1.73 (1.23-2.43)	0.002	2.06 (1.43-2.97)	< 0.001

[†]CSS, cancer-specific survival; LODDS, log odds of positive lymph node; HR, hazard ratio; CI, confidence interval.

Table S4. Univariable and multivariable Cox proportional regression analysis for the influence of LODDS on OS of the entire dataset

Characteristic	N (%)	Univariable analysis		Multivariable analysis	
		HR (95%CI)	P value	HR (95%CI)	P value
Age at diagnosis (year)					
≤62	300 (59.29)	1		1	
>62	206 (40.71)	3.46 (2.55-4.70)	< 0.001	2.55 (1.84-3.52)	< 0.0001
Sex					
Male	232 (45.85)	1		1	
Female	274 (54.15)	0.72 (0.54-0.96)	0.026	0.93 (0.69-1.25)	0.625
Race					
White	453 (89.53)	1			
Black	29 (5.73)	1.45 (0.83-2.56)	0.195		

Other	24 (4.74)	0.72 (0.34-1.53)	0.392		
Laterality					
Right	281 (55.53)	1			
Left	225 (44.47)	0.84 (0.62-1.13)	0.242		
Site					
Upper lobe	194 (38.34)	1		1	
Middle lobe	64 (12.65)	0.52 (0.30-0.91)	0.021	1.00 (0.55-1.83)	0.991
Lower lobe	196 (38.74)	0.86 (0.63-1.20)	0.378	1.02 (0.72-1.45)	0.900
Other	52 (10.28)	0.86 (0.52-1.44)	0.579	1.84 (1.05-3.22)	0.033
Histotype					
Large cell neuroendocrine	100 (05 40)	1		1	
carcinoma	129 (25.49)				
Carcinoid tumor	274 (54.15)	0.13 (0.09-0.18)	< 0.001	0.11 (0.07-0.19)	< 0.0001
Atypical carcinoid tumor	103 (20.36)	0.28 (0.18-0.41)	< 0.001	0.27 (0.16-0.45)	< 0.0001
Differentiation					
Well/moderately differentiated	201 (39.72)	1		1	
Poorly differentiated	97 (19.17)	6.61 (4.38-9.97)	< 0.001	1.65 (0.91-2.97)	0.098
/undifferentiated					
Unknown	208 (41.11)	1.92 (1.28-2.88)	0.002	1.45 (0.94-2.23)	0.095
T classification					
T1	209 (41.30)	1			
T2	190 (37.55)	1.00 (0.72-1.40)	0.996		
T3	74 (14.62)	1.43 (0.92-2.21)	0.112		
T4	33 (6.52)	1.28 (0.71-2.32)	0.409		
N classification					
N1	319 (63.04)	1		1	

N2	187 (36.96)	1.71 (1.28-2.29)	< 0.001	1.24 (0.90-1.71)	0.196
Surgery					
Sublobectomy	44 (8.70)	1			
Lobectomy	406 (80.24)	0.68 (0.42-1.09)	0.110		
Pneumonectomy	56 (11.07)	1.00 (0.56-1.80)	0.990		
Radiotherapy					
No	439 (86.76)	1		1	
Yes	67 (13.24)	1.84 (1.27-2.67)	0.001	1.17 (0.75-1.80)	0.491
Chemotherapy					
No	374 (73.91)	1		1	
Yes	132 (26.09)	1.99 (1.47-2.69)	< 0.001	0.45 (0.30-0.69)	0.000
LODDS as a categorica	al				
variable					
-1.44\(\leq\LODDS\)<-0.33	334 (66.01)	1		1	
-0.33\(\frac{1.14}{2}\)	172 (33.99)	1.52 (1.13-2.04)	0.006	1.66 (1.22-2.26)	0.001

[†]OS, overall survival; LODDS, log odds of positive lymph node; HR, hazard ratio; CI, confidence interval.

Table S5. Univariable and multivariable Cox proportional regression analysis for the influence of LODDS on CSS of the patients with number of dissected lymph nodes≤20

Characteristic		Univariable analy	ysis	Multivariable analysis	
	N (%) —	HR (95%CI)	P value	HR (95%CI)	P value
Age at diagnosis (year)					
≤62	269 (59.65)	1		1	
>62	182 (40.35)	2.77 (1.91-4.01)	< 0.001	2.20 (1.47-3.31)	< 0.001
Sex					
Male	203 (45.01)	1			
Female	248 (54.99)	0.78 (0.55-1.13)	0.190		
Race					
White	405 (89.80)	1		1	
Black	25 (5.54)	1.86 (0.97-3.56)	0.062	2.22 (1.09-4.52)	0.027
Other	21 (4.66)	1.02 (0.45-2.32)	0.970	0.67 (0.28-1.59)	0.367
Laterality					
Right	246 (54.55)	1			
Left	205 (45.45)	0.80 (0.56-1.16)	0.242		
Site					

Upper lobe	179 (39.69)	1		1	
Middle lobe	59 (13.08)	0.32 (0.15-0.70)	0.004	0.66 (0.28-1.57)	0.351
Lower lobe	179 (39.69)	0.67 (0.45-0.99)	0.043	0.97 (0.62-1.53)	0.912
Other	34 (7.54)	0.66 (0.31-1.37)	0.264	1.41 (0.60-3.31)	0.433
Histotype					
Large cell neuroendocrine	113 (25.06)	1		1	
carcinoma					
Carcinoid tumor	255 (56.54)	0.08 (0.05-0.13)	< 0.001	0.07 (0.03-0.14)	< 0.001
Atypical carcinoid tumor	83 (18.40)	0.21 (0.13-0.36)	< 0.001	0.18 (0.09-0.37)	< 0.001
Differentiation					
Well/moderately differentiated	178 (39.47)	1		1	
Poorly differentiated	84 (18.63)	9.54 (5.65-16.13)	< 0.001	1.76 (0.81-3.81)	0.154
/undifferentiated					
Unknown	189 (41.91)	2.12 (1.24-3.64)	0.006	1.50 (0.82-2.73)	0.187
T classification					
T1	193 (42.79)	1		1	
T2	170 (37.69)	0.91 (0.60-1.39)	0.660	0.67 (0.43-1.04)	0.073
T3	62 (13.75)	1.63 (0.97-2.75)	0.066	0.78 (0.44-1.38)	0.387
T4	26 (5.76)	1.51 (0.74-3.08)	0.256	1.40 (0.64-3.08)	0.402
N classification					
N1	283 (62.75)	1		1	
N2	168 (37.25)	1.56 (1.09-2.25)	0.016	1.07 (0.71-1.62)	0.729
Surgery					
Sublobectomy	43 (9.53)	1		1	
Lobectomy	365 (80.93)	0.62 (0.36-1.07)	0.085	1.17 (0.64-2.13)	0.620
Pneumonectomy	43 (9.53)	0.84 (0.41-1.71)	0.626	1.66 (0.75-3.67)	0.207

Radiotherapy					
No	387 (85.81)	1		1	
Yes	64 (14.19)	2.24 (1.47-3.41)	< 0.001	1.18 (0.71-1.94)	0.520
Chemotherapy					
No	336 (74.50)	1		1	
Yes	115 (25.50)	2.60 (1.80-3.75)	< 0.001	0.46 (0.27-0.77)	0.004
LODDS as a categoric	al				
variable					
-1.44\(\leq\LODDS\)<-0.33	286 (63.41)	1		1	
-0.33≤LODDS≤1.14	165 (36.59)	1.89 (1.32-2.72)	0.001	2.16 (1.46-3.19)	< 0.001

[†]CSS, cancer-specific survival; LODDS, log odds of positive lymph node; HR, hazard ratio; CI, confidence interval.

Table S6. Univariable and multivariable Cox proportional regression analysis for the influence of LODDS on OS of the patients with number of dissected lymph nodes≤20

Characteristic		Univariable analysis		Multivariable analysis	
	N (%)	HR (95%CI)	P value	HR (95%CI)	P value
Age at diagnosis (year)					
≤62	269 (59.65)	1		1	
>62	182 (40.35)	3.56 (2.56-4.96)	< 0.001	2.48 (1.75-3.51)	< 0.001
Sex					
Male	203 (45.01)	1		1	
Female	248 (54.99)	0.70 (0.51-0.96)	0.027	0.92 (0.66-1.28)	0.634
Race					
White	405 (89.80)	1			
Black	25 (5.54)	1.49 (0.81-2.76)	0.201		
Other	21 (4.66)	0.74 (0.33-1.68)	0.475		
Laterality					
Right	246 (54.55)	1			
Left	205 (45.45)	0.82 (0.60-1.13)	0.232		

Site					
Upper lobe	179 (39.69)	1		1	
Middle lobe	59 (13.08)	0.46 (0.25-0.84)	0.012	0.88 (0.45-1.72)	0.703
Lower lobe	179 (39.69)	0.84 (0.59-1.17)	0.301	1.07 (0.74-1.56)	0.704
Other	34 (7.54)	0.70 (0.36-1.35)	0.283	1.62 (0.80-3.31)	0.183
Histotype					
Large cell neuroendocrine	113 (25.06)	1		1	
carcinoma					
Carcinoid tumor	255 (56.54)	0.12 (0.08-0.17)	< 0.001	0.11 (0.06-0.19)	< 0.001
Atypical carcinoid tumor	83 (18.40)	0.23 (0.15-0.37)	< 0.001	0.23 (0.12-0.41)	< 0.001
Differentiation					
Well/moderately differentiated	178 (39.47)	1		1	
Poorly differentiated	84 (18.63)	8.17 (5.17-12.91)	< 0.001	1.82 (0.94-3.49)	0.074
/undifferentiated					
Unknown	189 (41.91)	2.24 (1.42-3.53)	0.001	1.58 (0.97-2.58)	0.065
T classification					
T1	193 (42.79)	1			
T2	170 (37.69)	1.01 (0.71-1.45)	0.937		
T3	62 (13.75)	1.46 (0.90-2.35)	0.123		
T4	26 (5.76)	1.46 (0.77-2.76)	0.251		
N classification					
N1	283 (62.75)	1		1	
N2	168 (37.25)	1.71 (1.25-2.34)	0.001	1.16 (0.82-1.63)	0.413
Surgery					
Sublobectomy	43 (9.53)	1			
Lobectomy	365 (80.93)	0.70 (0.42-1.14)	0.151		

Pneumonectomy	43 (9.53)	0.81 (0.42-1.57)	0.537		
Radiotherapy					
No	387 (85.81)	1		1	
Yes	64 (14.19)	1.94 (1.33-2.84)	0.001	1.20 (0.76-1.89)	0.427
Chemotherapy					
No	336 (74.50)	1		1	
Yes	115 (25.50)	2.14 (1.55-2.96)	< 0.001	0.42 (0.26-0.67)	< 0.001
LODDS as a categoric	cal				
variable					
-1.44 <u><</u> LODDS<-0.33	286 (63.41)	1		1	
-0.33≤LODDS≤1.14	165 (36.59)	1.65 (1.20-2.26)	0.002	1.75 (1.25-2.43)	0.001

[†]OS, overall survival; LODDS, log odds of positive lymph node; HR, hazard ratio; CI, confidence interval.

Table S7. Univariable and multivariable Cox proportional regression analysis for the influence of LODDS on CSS of the patients with number of dissected lymph nodes≥6

Characteristic		Univariable analysis		Multivariable analysis	
	N (%) —	HR (95%CI)	P value	HR (95%CI)	P value
Age at diagnosis (year)					
≤62	231 (60.16)	1		1	
>62	153 (39.84)	3.00 (2.00-4.50)	< 0.001	2.35 (1.50-3.67)	< 0.001
Sex					
Male	170 (44.27)	1			
Female	214 (55.73)	0.85 (0.57-1.26)	0.409		
Race					
White	342 (89.06)	1		1	
Black	22 (5.73)	1.96 (0.98-3.90)	0.055	2.39 (1.13-5.07)	0.023
Other	20 (5.21)	1.33 (0.62-2.88)	0.468	1.09 (0.47-2.54)	0.833
Laterality					
Right	212 (55.21)	1			
Left	172 (44.79)	0.95 (0.64-1.42)	0.803		
Site					
Upper lobe	137 (35.68)	1		1	
Middle lobe	46 (11.98)	0.34 (0.14-0.79)	0.013	0.70 (0.27-1.79)	0.452
Lower lobe	152 (39.58)	0.65 (0.41-1.01)	0.056	0.97 (0.61-1.56)	0.901
Other	49 (12.76)	0.80 (0.43-1.48)	0.470	0.99 (0.44-2.21)	0.978

TT: 4.4					
Histotype	05 (07 0.0)				
Large cell neuroendocrine	97 (25.26)	1		1	
carcinoma					
Carcinoid tumor	202 (52.60)	0.10 (0.06-0.17)	< 0.001	0.09 (0.04-0.19)	< 0.001
Atypical carcinoid tumor	85 (22.14)	0.27 (0.16-0.45)	< 0.001	0.21 (0.10-0.43)	< 0.001
Differentiation					
Well/moderately differentiated	153 (39.84)	1		1	
Poorly differentiated	74 (19.27)	7.00 (4.02-12.18)	< 0.001	1.66 (0.73-3.76)	0.224
/undifferentiated					
Unknown	157 (40.89)	1.73 (0.99-3.04)	0.056	1.47 (0.78-2.75)	0.229
T classification					
T1	141 (36.72)	1		1	
T2	152 (39.58)	0.79 (0.49-1.28)	0.335	0.72 (0.43-1.20)	0.211
T3	62 (16.15)	1.59 (0.92-2.74)	0.098	1.17 (0.63-2.18)	0.619
T4	29 (7.55)	1.67 (0.85-3.28)	0.138	2.10 (0.89-4.95)	0.092
N classification					
N1	241 (62.76)	1		1	
N2	143 (37.24)	1.31 (0.88-1.96)	0.181	0.99 (0.63-1.54)	0.956
Surgery					
Sublobectomy	21 (5.47)	1		1	
Lobectomy	310 (80.73)	0.59 (0.27-1.28)	0.178	0.52 (0.23-1.18)	0.117
Pneumonectomy	53 (13.80)	1.14 (0.49-2.66)	0.768	0.99 (0.39-2.52)	0.989
Radiotherapy					
No	336 (87.50)	1		1	
Yes	48 (12.50)	1.91 (1.17-3.13)	0.010	0.78 (0.44-1.38)	0.393
Chemotherapy	, ,	, ,		, ,	

No	284 (73.96)	1		1	
Yes	100 (26.04)	2.46 (1.65-3.67)	< 0.001	0.70 (0.41-1.22)	0.208
LODDS as a categorical variable	I				
-1.44 <u><</u> LODDS<-0.33	300 (78.12)	1		1	
-0.33≤LODDS≤1.14	84 (21.88)	2.16 (1.42-3.28)	< 0.001	2.84 (1.78-4.50)	< 0.001

[†]CSS, cancer-specific survival; LODDS, log odds of positive lymph node; HR, hazard ratio; CI, confidence interval.

Table S8. Univariable and multivariable Cox proportional regression analysis for the influence of LODDS on OS of the patients with number of dissected lymph nodes≥6

		Univariable analysis		Multivariable analysis	
Characteristic	N (%) —	HR (95%CI)	P value	HR (95%CI)	P value
Age at diagnosis (year)					
≤62	231 (60.16)	1		1	
>62	153 (39.84)	3.70 (2.60-5.27)	< 0.001	2.63 (1.80-3.83)	< 0.001
Sex					
Male	170 (44.27)	1		1	
Female	214 (55.73)	0.69 (0.49-0.96)	0.028	0.86 (0.60-1.24)	0.423
Race					
White	342 (89.06)	1			
Black	22 (5.73)	1.67 (0.90-3.10)	0.104		
Other	20 (5.21)	0.93 (0.43-1.99)	0.844		
Laterality					
Right	212 (55.21)	1			
Left	172 (44.79)	0.88 (0.62-1.23)	0.449		
Site					
Upper lobe	137 (35.68)	1		1	
Middle lobe	46 (11.98)	0.58 (0.31-1.09)	0.089	1.23 (0.61-2.49)	0.563
Lower lobe	152 (39.58)	0.89 (0.61-1.31)	0.567	1.35 (0.90-2.02)	0.149
Other	49 (12.76)	0.96 (0.56-1.63)	0.870	2.22 (1.21-4.07)	0.010

Histotype					
Large cell neuroendocrine	97 (25.26)	1		1	
carcinoma					
Carcinoid tumor	202 (52.60)	0.14 (0.10-0.21)	< 0.001	0.11 (0.06-0.21)	< 0.001
Atypical carcinoid tumor	85 (22.14)	0.27 (0.17-0.43)	< 0.001	0.22 (0.12-0.40)	< 0.001
Differentiation					
Well/moderately differentiated	153 (39.84)	1		1	
Poorly differentiated	74 (19.27)	6.50 (4.01-10.54)	< 0.001	1.78 (0.91-3.47)	0.091
/undifferentiated					
Unknown	157 (40.89)	1.99 (1.23-3.20)	0.005	1.61 (0.97-2.66)	0.066
T classification					
T1	141 (36.72)	1			
T2	152 (39.58)	0.91 (0.61-1.35)	0.639		
T3	62 (16.15)	1.31 (0.80-2.15)	0.283		
T4	29 (7.55)	1.44 (0.78-2.66)	0.241		
N classification					
N1	241 (62.76)	1		1	
N2	143 (37.24)	1.53 (1.09-2.14)	0.014	1.25 (0.86-1.81)	0.247
Surgery					
Sublobectomy	21 (5.47)	1			
Lobectomy	310 (80.73)	0.75 (0.37-1.55)	0.443		
Pneumonectomy	53 (13.80)	1.14 (0.52-2.52)	0.745		
Radiotherapy					
No	336 (87.50)	1		1	
Yes	48 (12.50)	1.61 (1.04-2.50)	0.034	0.88 (0.53-1.48)	0.639
Chemotherapy					

No	284 (73.96)	1		1	
Yes	100 (26.04)	1.95 (1.38-2.75)	< 0.001	0.57 (0.35-0.91)	0.020
LODDS as a categorical variable	1				
-1.44 <u><</u> LODDS<-0.33	300 (78.12)	1		1	
-0.33≤LODDS≤1.14	84 (21.88)	1.97 (1.37-2.84)	< 0.001	2.37 (1.59-3.54)	< 0.001

[†]OS, overall survival; LODDS, log odds of positive lymph node; HR, hazard ratio; CI, confidence interval.

 Table S9. HRs for subgroups

~ -		CSS		os	
Subgroups	N (%) —	HR (95%CI)	P value	HR (95%CI)	P value
Age at diagnosis (year)					
≤62	300 (59.29)	2.52 (1.42-4.47)	0.002	2.20 (1.34-3.63)	0.002
>62	206 (40.71)	1.63 (0.98-2.69)	0.058	1.21 (0.80-1.82)	0.369
Sex					
Male	232 (45.85)	3.96 (2.15-7.32)	< 0.001	2.06 (1.29-3.27)	0.002
Female	274 (54.15)	1.53 (0.90-2.58)	0.116	1.43 (0.92-2.23)	0.110
Laterality					
Right	281 (55.53)	1.67 (1.04-2.67)	0.035	1.56 (1.04-2.35)	0.033
Left	225 (44.47)	2.88 (1.52-5.45)	0.001	2.00 (1.20-3.32)	0.008
Site					
Pulmonary lobe	454 (89.72)	2.10 (1.44-3.08)	< 0.001	1.67 (1.21-2.31)	0.002
Other	52 (10.28)	4.65 (0.25-87.17)	0.304	1.45 (0.37-5.73)	0.594
Histotype					
Large cell neuroendocrine	129 (25.49)	1.96 (1.19-3.24)	0.009	1.55 (1.12.2.54)	0.014
carcinoma				1.75 (1.12-2.74)	0.014
Carcinoid tumor	274 (54.15)	0.75 (0.32-1.73)	0.500	0.79 (0.43-1.43)	0.435
Atypical carcinoid tumor	103 (20.36)	2.67 (0.90-7.90)	0.076	2.40 (1.01-5.74)	0.048
Differentiation					
Well/moderately differentiated	201 (39.72)	0.70 (0.27-1.80)	0.455	0.79 (0.37-1.70)	0.551
Poorly differentiated	97 (19.17)	1.96 (1.06-3.61)	0.031	1.45 (0.85-2.48)	0.174

/undifferentiated					_
Unknown	208 (41.11)	3.38 (1.70-6.70)	< 0.001	2.31 (1.40-3.82)	0.001
T classification					
T1	209 (41.30)	2.10 (1.15-3.84)	0.016	1.65 (0.98-2.77)	0.058
T2	190 (37.55)	1.95 (1.00-3.80)	0.048	1.36 (0.81-2.28)	0.243
T3-4	107 (21.15)	1.75 (0.72-4.22)	0.217	1.28 (0.59-2.77)	0.530
N classification					
N1	319 (63.04)	1.99 (1.14-3.45)	0.015	1.56 (0.98-2.49)	0.060
N2	187 (36.96)	2.24 (1.27-3.96)	0.006	1.87 (1.20-2.93)	0.006
Surgery					
Sublobectomy	44 (8.70)	4.64 (0.37-57.53)	0.233	0.57 (0.17-1.92)	0.366
Lobectomy	406 (80.24)	2.53 (1.65-3.89)	< 0.001	2.03 (1.41-2.92)	< 0.001
Pneumonectomy	56 (11.07)	2.19 (0.46-10.51)	0.325	1.67 (0.51-5.53)	0.400

[†]HR for CSS were evaluated based on multivariable Cox proportional regression model adjusted by age, race, site, histotype, differentiation, T classification, N classification, surgery, radiotherapy and chemotherapy.

[‡]HR for OS were evaluated based on multivariable Cox proportional regression model adjusted by age, race, site, histotype, differentiation, N classification, radiotherapy and chemotherapy.

[§]CSS, cancer-specific survival; LODDS, log odds of positive lymph node; OS, overall survival; HR, hazard ratio; CI, confidence interval.

Table S10. Baseline characteristics of derivation dataset and external validation dataset

Chamatanistia	Total	Derivation dataset	External validation dataset	D l *
Characteristic	(n=506)	(n=300)	(n=206)	P value*
Age at diagnosis (year)				0.280
≤62	300 (59.29)	172 (57.33)	128 (62.14)	
>62	206 (40.71)	128 (42.67)	78 (37.86)	
Sex				0.314
Male	232 (45.85)	132 (44.00)	100 (48.54)	
Female	274 (54.15)	168 (56.00)	106 (51.46)	
Race				< 0.001
White	453 (89.53)	281 (93.67)	172 (83.50)	
Black	29 (5.73)	15 (5.00)	14 (6.80)	
Other	24 (4.74)	4 (1.33)	20 (9.71)	
Laterality				0.308
Right	281 (55.53)	161 (53.67)	120 (58.25)	
Left	225 (44.47)	139 (46.33)	86 (41.75)	
Site				0.360
Upper lobe	194 (38.34)	124 (41.33)	70 (33.98)	
Middle lobe	64 (12.65)	34 (11.33)	30 (14.56)	
Lower lobe	196 (38.74)	113 (37.67)	83 (40.29)	
Other	52 (10.28)	29 (9.67)	23 (11.17)	
Histotype				0.100
Large cell neuroendocrine	120 (25 40)	96 (29 67)	42 (20.97)	
carcinoma	129 (25.49)	86 (28.67)	43 (20.87)	
Carcinoid tumor	274 (54.15)	152 (50.67)	122 (59.22)	
Atypical carcinoid tumor	103 (20.36)	62 (20.67)	41 (19.90)	

Differentiation				0.237
Well/moderately differentiated	201 (39.72)	120 (40.00)	81 (39.32)	
Poorly differenti	ated 97 (19.17)	64 (21.33)	33 (16.02)	
/undifferentiated				
Unknown	208 (41.11)	116 (38.67)	92 (44.66)	
T classification				0.387
T1	209 (41.30)	128 (42.67)	81 (39.32)	
T2	190 (37.55)	114 (38.00)	76 (36.89)	
Т3	74 (14.62)	43 (14.33)	31 (15.05)	
T4	33 (6.52)	15 (5.00)	18 (8.74)	
N classification				0.468
N1	319 (63.04)	193 (64.33)	126 (61.17)	
N2	187 (36.96)	107 (35.67)	80 (38.83)	
Surgery				0.483
Sublobectomy	44 (8.70)	24 (8.00)	20 (9.71)	
Lobectomy	406 (80.24)	246 (82.00)	160 (77.67)	
Pneumonectomy	56 (11.07)	30 (10.00)	26 (12.62)	
Radiotherapy				0.733
No	439 (86.76)	259 (86.33)	180 (87.38)	
Yes	67 (13.24)	41 (13.67)	26 (12.62)	
Chemotherapy				0.111
No	374 (73.91)	214 (71.33)	160 (77.67)	
Yes	132 (26.09)	86 (28.67)	46 (22.33)	
Number of dissected lymph nod	es 9.00 (6.00-14.75)	9.00 (6.00-14.00)	(6.00-15.00)	0.299
Number of positive lymph node	s 2.00 (1.00-3.00)	1.00 (1.00-2.00)	(1.00-3.00)	0.350
LODDS as a continuous variable	e -0.49 (-0.790.22)	-0.50 (-0.770.22)	-0.49 (-0.790.22)	0.916

LODDS as a categorical variable				0.845
-1.44≤LODDS<-0.33	334 (66.01)	197 (65.67)	137 (66.50)	
-0.33≤LODDS≤1.14	172 (33.99)	103 (34.33)	69 (33.50)	

[†]Data are listed as median (IQR) or n (%). *P values for Mann-Whitney test or Chi square test by comparing the basic characteristics in the derivation and external validation datasets.

[‡]LODDS, log odds of positive lymph node.

Table S11. The IDI and continuous-NRI comparing nomogram with AJCC 8th TNM staging system

	IDI		Continuous-NRI	
Endpoint -	95%CI	P value	95%CI	P value
Derivation dataset				
1-year CSS	0.249 (0.389-0.161)	< 0.001	0.721 (0.825-0.554)	< 0.001
3-year CSS	0.391 (0.519-0.243)	< 0.001	0.645 (0.743-0.414)	< 0.001
5-year CSS	0.42 (0.537-0.265)	< 0.001	0.627 (0.768-0.403)	< 0.001
1-year OS	0.256 (0.368-0.166)	< 0.001	0.649 (0.778-0.453)	< 0.001
3-year OS	0.349 (0.46-0.208)	< 0.001	0.492 (0.653-0.32)	< 0.001
5-year OS	0.364 (0.457-0.237)	< 0.001	0.523 (0.662-0.324)	< 0.001
External validation dataset				
1-year CSS	0.165 (0.356-0.065)	< 0.001	0.46 (0.683-0.178)	< 0.001
3-year CSS	0.303 (0.427-0.171)	< 0.001	0.539 (0.701-0.308)	< 0.001
5-year CSS	0.321 (0.442-0.146)	< 0.001	0.496 (0.688-0.283)	< 0.001
1-year OS	0.121 (0.263-0.057)	< 0.001	0.379 (0.647-0.162)	< 0.001
3-year OS	0.257 (0.384-0.138)	< 0.001	0.456 (0.653-0.23)	< 0.001
5-year OS	0.274 (0.382-0.11)	< 0.001	0.451 (0.611-0.24)	< 0.001

[†]CSS, cancer-specific survival; IDI, integrated discrimination improvement; LODDS, log odds of positive lymph node; NRI, net reclassification improvement; OS, overall survival.

Figure legends

Figure 1. Selection of study cohort from the SEER database. AC: atypical carcinoid; LCNEC: large cell neuroendocrine carcinoma; SCLC: small cell lung carcinoma; SEER: Surveillance, Epidemiology, and End Results; LN: lymph node; TNM: tumor-node-metastasis.

Figure 2. Restricted cubic spline fitting for the association between LODDS levels with the HRs of LODDS for CSS (A) and OS (B). LODDS: log odds of positive lymph nodes; CSS: lung cancer-specific survival; OS: overall survival; HR: hazard ratio; CI: confidence interval.

Figure 3. Nomograms to predict 1-, 3- and 5-year CSS (A) and OS (B) for patients with node-positive lung neuroendocrine carcinoma after surgery. CSS: lung cancer-specific survival; OS: overall survival; LODDS: log odds of positive lymph nodes.

Figure 4. Calibration plots of the nomograms to predict CSS and OS of the derivation dataset (A, B) and external validation dataset (C, D). CSS: lung cancer-specific survival; OS: overall survival.

Figure S1. Kaplan-Meier estimates of CSS (A) and OS (B) for entire dataset according to LODDS. CSS: lung cancer-specific survival; OS: overall survival; LODDS: log odds of positive lymph nodes.

Figure S2. Decision curve analysis of AJCC 8th TNM staging system and nomogram for 3-, and 5-year CSS (A, B), OS (C, D) prediction in the derivation dataset. CSS: lung cancer-specific survival; OS: overall survival; TNM: tumor-node-metastasis.

Figure S3. Decision curve analysis of AJCC 8th TNM staging system and nomogram for 3-, and 5-year CSS (A, B), OS (C, D) prediction in the external validation dataset. CSS: lung cancer-specific survival; OS: overall survival; TNM: tumor-node-metastasis.

Figure S4. Online nomograms to predict CSS (A) and OS (B) for patients with node-positive lung neuroendocrine carcinoma after surgery. CSS: lung cancer-specific survival; OS: overall survival; LODDS: log odds of positive lymph nodes.

Fig 1.




Fig 2




Fig 3




Fig 4




Fig S1




Fig S2




Fig S3




Fig S4

Α

Dynamic nomogram for CSS of node-positive lung neuroendocrine carcinoma after surgery



В

Dynamic nomogram for OS of node-positive lung neuroendocrine carcinoma after surgery

